bpc 157 safety adverse effects human studies BPC-157 Explained: Benefits, & Oral vs Injectable Options What Science ACTUALLY Says About
Description
Five years of protection for a new molecular entity means that no ANDA can be approved and in the first four years, none can even be filed regardless of the patent situation
They do not enter the therapeutic-good supply chain and are not represented as therapeutic goods under the Therapeutic Goods Act 1989
For patients who want both approaches, a common protocol is: PRP session(s) with an orthopedic provider for the concentrated local stimulus, plus a BPC-157 protocol from Moonshot to sustain the healing environment between PRP sessions
10.3748/wjg.v24.i48.5462 [DOI] [PMC free article] [PubMed] [Google Scholar] Duzel, A
